Upon TB therapy, the rate of decline in IP-10 level, between baseline and 26-week measurements, was significantly steeper in TB+HIV− patients when compared with TB+HIV+ patients (p = 0.02); where the median fold changes in IP-10 concentrations were 0.24 (IQR: 0.08–0.37) in TB+HIV− subjects and 0.41 (IQR: 0.23–0.67) in TB+HIV+ subjects (Figure 4B). This evidence concerns the gene CXCL10 and tuberculosis.